TLDR
- VVOS surges as Vivos unveils $4.5M debt exchange plan
- Vivos debt swap plan boosts market confidence in VVOS
- VVOS rallies after Vivos targets debt relief and liquidity
- Vivos stock jumps as Nasdaq compliance plan gains support
- Debt exchange deal sends Vivos Therapeutics stock higher
Vivos Therapeutics (VVOS) stock jumped on Friday after the company announced a debt exchange plan with Streeterville Capital. VVOS traded at $0.8965, up 29.50%, after an early spike above $1.30. The move reflected stronger market interest as Vivos moved to reduce debt pressure and support Nasdaq compliance.
Vivos Therapeutics, Inc., VVOS
Vivos Therapeutics Stock Gains After Debt Exchange Plan
Vivos Therapeutics said it reached a binding agreement with senior secured lender Streeterville Capital. The deal allows Vivos to exchange up to $4.5 million of debt. The exchange will include perpetual, nonconvertible preferred stock and common shares.
The company also secured short-term relief from Streeterville under the agreement. Streeterville will suspend debt repayment calls for 90 days after the exchange becomes effective. It will also suspend sales of company securities for 60 days.
The plan aims to improve Vivos’ balance sheet and support its equity remediation plan. Nasdaq listing rules require companies to maintain specific stockholders’ equity levels. Therefore, the exchange could help Vivos address pressure tied to continued listing standards.
Debt Relief Supports Liquidity And Nasdaq Compliance Efforts
Vivos said the exchange depends on one or more qualifying equity financings. The company must complete those financings on terms it accepts. The company noted that no financing or exchange remains guaranteed.
The proposed structure could reduce debt service obligations and ease near-term cash pressure. The 90-day repayment suspension may support liquidity during the remediation period. This gives Vivos more room to manage operations and capital needs.
The company announced for informational purposes only. It said any securities offering would follow applicable securities laws. Any future offering would also require definitive offering documents.
Sleep Center Deal Adds Background To Vivos Strategy
Vivos focuses on medical devices and healthcare services for sleep-related breathing disorders. Its main areas include obstructive sleep apnea and related chronic health conditions. The company has worked to expand beyond device sales into healthcare service operations.
In June 2025, Vivos acquired the operating assets of The Sleep Center of Nevada. SCN operates the largest medical sleep center network in Nevada. The deal marked Vivos’ first major sleep testing center and medical sleep practice acquisition.
That acquisition changed the company’s business model and revenue outlook. Streeterville supported the transaction through debt financing, while New Seneca Partners provided equity backing. Consequently, the latest debt exchange plan fits Vivos’ wider push to strengthen its capital structure.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
